| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 19.315 | 17.245 | 14.575 | 27.345 | 89.358 | 98.040 | 137.393 | 219.433 | 254.441 | 206.067 |
| Total Income - EUR | 19.315 | 25.159 | 22.676 | 48.835 | 89.359 | 98.613 | 142.302 | 219.442 | 257.127 | 210.173 |
| Total Expenses - EUR | 20.374 | 24.163 | 20.557 | 42.494 | 81.884 | 77.982 | 113.316 | 187.838 | 226.312 | 204.428 |
| Gross Profit/Loss - EUR | -1.059 | 996 | 2.118 | 6.341 | 7.475 | 20.631 | 28.986 | 31.605 | 30.816 | 5.745 |
| Net Profit/Loss - EUR | -1.638 | 824 | 260 | 5.852 | 6.582 | 19.683 | 28.016 | 29.147 | 28.244 | 525 |
| Employees | 2 | 2 | 2 | 3 | 3 | 5 | 4 | 3 | 2 | 3 |
Check the financial reports for the company - Provet Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 67.750 | 66.577 | 139.635 | 173.542 | 164.992 | 157.162 | 215.166 | 199.742 | 196.112 | 150.678 |
| Current Assets | 33.152 | 22.507 | 11.861 | 16.108 | 10.137 | 26.523 | 58.876 | 50.219 | 48.454 | 73.346 |
| Inventories | 1.592 | 477 | 87 | 513 | 8 | 123 | 4.803 | 9.717 | 7.277 | 25.996 |
| Receivables | 9.924 | 10.682 | 10.909 | 10.190 | 9.055 | 10.622 | 19.551 | 21.615 | 34.651 | 28.379 |
| Cash | 21.637 | 11.348 | 865 | 5.406 | 1.075 | 15.777 | 34.522 | 18.887 | 6.526 | 18.972 |
| Shareholders Funds | 103.019 | 80.524 | 71.322 | 75.865 | 80.977 | 113.140 | 124.745 | 154.279 | 182.055 | 181.563 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 27.907 | 45.179 | 115.420 | 128.353 | 94.152 | 84.560 | 149.297 | 95.682 | 62.512 | 42.461 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7500 - 7500" | |||||||||
| CAEN Financial Year |
7500
|
|||||||||
Comments - Provet Pharm Srl